A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs and...

Update Il y a 4 ans
Reference: EUCTR2009-010739-42

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the efficacy of tadalafil 5 mg once daily for 12 weeks compared with placebo in improving the IPSS in men with signs and symptoms of BPH, also referred to as BPH-LUTS (lower urinary tract symptoms).


Inclusion criteria

  • benign prostatic hyperplasia (BPH)